New COVID-19 treatment pills come as Utah omicron rates increase
SALT LAKE CITY — Just as health officials estimate at least 30% of COVID-19 cases in Utah are omicron, two new antiviral COVID pills have been authorized for use.
The Utah Department of Health currently estimates close to a third of all cases in the state may now be omicron.
As Omicron spreads rapidly across the United States and in Utah, the Food and Drug Administration has issued an emergency authorization for two COVID-19 at-home treatments, in the form of a pill.
On Wednesday, Pfizer’s Paxlovid, an oral antiviral pill, was approved for manufacture and distribution to individuals, ages 12 or older who weigh at least 88 pounds, with mild-to-moderate COVID-19.
On Thursday, the FDA authorized Merck’s molnupiravir; another potential pill to combat COVID.
Distinct differences between the pills’ effects and safety levels indicate Merck’s pill will play a much smaller role in treatment than previously thought. Molnupiravir carries a safety warning for pregnant women and warns of the potential for birth defects.
Also, Merck’s pill was shown to be much three times less effective than Paxlovid in reducing hospitalization and death from COVID-19 during testing.
Neither drug is considered a substitute for vaccinations and boosters. The antiviral COVID pills will be used to treat symptoms for approved groups for no more than five days.
Today’s Top Stories
- Controversial homecoming dress code ends in protest
- Intermountain Healthcare purchases land near Ephraim
- Fatal crash near Strawberry Reservoir closes SR-40
- Motorhome crash in Idaho sends two Utahns to the hospital
- Officer-involved shooting kills one, sends officer to hospital
- Salt Lake County Dems call for immediate resignation of Sen. Gene Davis
- Draper City suing Geneva Rock, the mining company at Point of the Mountain
- Salt Lake City Police respond to five different incidents with weapons
- Utah homes have some of the highest levels of radon gas
- A new chance for a fighting chance against ovarian cancer